DNA sequencing

MGI Showcases Life Science Excellence at ESCMID Global 2024 with Latest DNBSEQ-E25 Sequencer and New Partnership with ABL Diagnostics

Retrieved on: 
Lundi, avril 29, 2024
Infection, Congress, E25, Genomics, ABL, Laboratory, Health, ESCMID, Software, Business development, ECCMID, Partnership, Research, Workflow, NGS, DNA, DNB, Patient, Microbiology, MGI, Database, HIV, PFI, Exhibition, FASTQ, DNA sequencing, Tuberculosis

During the event taking place from 27-30 April in Barcelona, MGI and ABL Diagnostics (Woippy, France, Euronext: ABLD – ISIN: FR001400AHX6) are pleased to announce its partnership and the compatibility of ABL Diagnostics' DeepChek® assays with MGI's DNBSEQ™ platforms.

Key Points: 
  • During the event taking place from 27-30 April in Barcelona, MGI and ABL Diagnostics (Woippy, France, Euronext: ABLD – ISIN: FR001400AHX6) are pleased to announce its partnership and the compatibility of ABL Diagnostics' DeepChek® assays with MGI's DNBSEQ™ platforms.
  • "Once again, MGI showcases our commitment to supporting healthcare and scientific research and applications across Europe and Africa.
  • We at MGI believe that the power and potential of genomics are boundless," said Dr. Yong Hou, General Manager of MGI Europe and Africa.
  • Moreover, at this year's ESCMID Global 2024, MGI announced a technical assessment of solutions by ABL Diagnostics (ABL), a Euronext-listed company that develops molecular biology assays and software for microbiology genotyping.

TwinStrand Biosciences Initiates Regulatory Approval Process for Duplex Sequencing Mutagenesis Assays with OECD

Retrieved on: 
Mercredi, avril 24, 2024
Mutation, News, Organization, Safety, Duplex sequencing, Cosmetics, Health, DNA, Food, Genome, Drug development, DNA sequencing, SPSF, OECD, Vaccine

OECD approves application to initiate regulatory acceptance process for ecNGS technology, an improved method for mutagenesis testing.

Key Points: 
  • OECD approves application to initiate regulatory acceptance process for ecNGS technology, an improved method for mutagenesis testing.
  • This significant milestone will accelerate commencement of the global regulatory acceptance process for error-corrected Next Generation Sequencing (ecNGS) for mutagenesis testing.
  • TwinStrand DuplexSeq™ mutagenesis assays outperform traditional mutagenicity methods by providing additional mechanistic insights, potentially reducing animal testing while enhancing detection of mutagenic compounds.
  • "Gaining global approval for Duplex Sequencing to become the standard for mutagenesis testing is a huge achievement for our team," said Ron Andrews, CEO of TwinStrand.

Next Generation Sequencing (NGS) Data Analysis Global Strategic Business Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Mardi, avril 9, 2024
Technology, Data Analytics, Professional Services, Data Management, Growth, Data analysis, NGS, DNA sequencing, Medicine, Workflow

The "Next Generation Sequencing (NGS) Data Analysis - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next Generation Sequencing (NGS) Data Analysis - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The Next Generation Sequencing (NGS) Data Analysis market is witnessing robust growth, driven by its ability to unravel critical scientific clues.
  • NGS data analysis encompasses insights into file formats and downstream analysis methods, highlighting its importance in scientific research.
  • The Next Generation Sequencing (NGS) Data Analysis market in the U.S. is estimated at US$321.4 Million in the year 2023.

SYNPET to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024

Retrieved on: 
Mercredi, avril 3, 2024
Health, Growth, Capsule, Probiotic, NGS, Research, Lactic acid, Interview, Kansas City Convention Center, DNA sequencing, Immunity, Facial muscles, Fermentation, Pet, Aggression

TAIPEI, April 3, 2024 /PRNewswire/ -- SYNPET, a subsidiary brand of SYNBIO TECH, a leading lactobacillus manufacturer based in Taiwan, is proud to announce its participation at the upcoming Petfood Forum 2024.

Key Points: 
  • TAIPEI, April 3, 2024 /PRNewswire/ -- SYNPET, a subsidiary brand of SYNBIO TECH, a leading lactobacillus manufacturer based in Taiwan, is proud to announce its participation at the upcoming Petfood Forum 2024.
  • At Petfood Forum 2024, SYNPET will showcase its headlining product:
    GABA 20: A postbiotic designed for pets to boost immunity, reduce stress and aggressive behavior.
  • "We are thrilled to participate in Petfood Forum 2024 and introduce our innovative probiotic solutions to the pet food industry," said Tammy Chang, Vice President of SYNBIO TECH.
  • For media inquiries or to schedule an interview with SYNPET representatives at Petfood Forum 2024, please contact:

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

Retrieved on: 
Jeudi, mars 7, 2024
Health, Infectious Diseases, Health Technology, Research, Science, Pharmaceutical, Biotechnology, DNA sequencing, Therapy, Innovation, Doctor of Philosophy, Intelligence, Next Generation, HIMSS, Synthetic biology, Language, Silicon, Drug discovery, Entrepreneurship, Conference, Protein engineering, Natural language processing, Pharmacy, LLM, DNA-binding protein, InterSystems, Medicine, Fruit, Protein, Gene, Knowledge, Biology, Artificial intelligence, Natural language, NLP

The Company’s model uniquely combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology.

Key Points: 
  • The Company’s model uniquely combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology.
  • Central to the success of BioStrand's Foundation AI Model is its utilization of its patented HYFT technology, a sophisticated framework designed to identify and leverage universal fingerprint™ patterns across the biosphere.
  • The Advanced Foundation AI model employs a distinctive approach known as "LLM stacking" to intelligently combine different LLMs, with the HYFTs linked to specific features found in various LLMs.
  • Our presentation will focus on introducing our groundbreaking Universal Foundation AI Model for Multiscale Biological Data Integration.

MiDOG Animal Diagnostics Revolutionizes Veterinary Care with Expanded Diagnostic Solutions for All Animal Species

Retrieved on: 
Lundi, février 19, 2024
DNA sequencing, Therapy, Infection, Bird, Amphibian, Reptile, DVM, Veterinary medicine, Ageing, Culture, Animal, Dog, NGS, Veterinarian, University, Health, Oral hygiene, Cat, Mammal, Patient, Diagnosis, FMT, Research, AMR, Vaccine

TUSTIN, Calif., Feb. 19, 2024 /PRNewswire/ -- MiDOG Animal Diagnostics LLC, a prominent leader in microbiome-based veterinary diagnostic solutions employing Next Generation DNA Sequencing analysis, has unveiled a revamped branding strategy in 2024.

Key Points: 
  • TUSTIN, Calif., Feb. 19, 2024 /PRNewswire/ -- MiDOG Animal Diagnostics LLC, a prominent leader in microbiome-based veterinary diagnostic solutions employing Next Generation DNA Sequencing analysis, has unveiled a revamped branding strategy in 2024.
  • The updated branding emphasizes the adaptability of MiDOG's technology across all animal species, departing from its previous emphasis on canine diagnostics.
  • By extending its diagnostic capabilities to encompass a diverse range of animal species, MiDOG aims to equip veterinarians with the tools needed to address acute, chronic, and non-responsive infections effectively.
  • The innovation at MiDOG Animal Diagnostics LLC is its microbiome-based comprehensive test, covering bacterial, fungal, and antimicrobial resistance (AMR) analysis.

New IBM LinuxONE 4 Express to Offer Cost Savings and Client Value through a Cyber Resilient Hybrid Cloud and AI Platform

Retrieved on: 
Mardi, février 6, 2024
Spiking, IBM, IBM Z, OpenShift, Product management, Linux on IBM Z, Express, DNA sequencing, Pressure, Practice, Support group, SBM, Ecosystem, University College London, AI, Research, GDPS, University, Digital, IBM Parallel Sysplex, Pennant, Exponential, Linux, Data analysis, Roger Hawkins (drummer), DS8000, Student, Tres, Workload, Humanities, Organization

Newest IBM LinuxONE system is engineered to deliver cybersecurity, resiliency, scalability and AI inferencing for hybrid cloud environments.

Key Points: 
  • Newest IBM LinuxONE system is engineered to deliver cybersecurity, resiliency, scalability and AI inferencing for hybrid cloud environments.
  • IBM Secure Execution for Linux is a hardware-based security technology that is now built into IBM LinuxONE 4 Express.
  • IBM Business Partners can learn more about the skills required to install, deploy, service and resell IBM LinuxONE 4 Express here .
  • The new IBM LinuxONE 4 Express, starting at $135,0005, will be generally available6 from IBM and certified business partners on February 20, 2024.

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

Retrieved on: 
Samedi, décembre 9, 2023
Senior, NGS, Neoplasm, PB, MRD, FDA, Jan Vansina, Bone marrow, Mantle cell lymphoma, Blood, Multiple myeloma, Health, MD, Society, ADPT, Minimal residual disease, ASH, University, Non-Hodgkin lymphoma, Abstract, DNA sequencing, Associate professor, Genetics, Meeting, Assistant, OS, PFS, Public health, MCL, Pharmaceutical industry

The data are being presented in more than 30 abstracts at the 65th Annual Meeting of the American Society of Hematology (ASH), December 9-12 in San Diego, California.

Key Points: 
  • The data are being presented in more than 30 abstracts at the 65th Annual Meeting of the American Society of Hematology (ASH), December 9-12 in San Diego, California.
  • “The already-substantial body of evidence supporting clonoSEQ’s prognostic value and clinical actionability is expanding in several important ways at ASH this year,” said Susan Bobulsky, Senior Vice President, Diagnostics, Adaptive Biotechnologies.
  • At this timepoint, MRD status from both PB and BM were similarly prognostic of patients’ progression-free survival (PFS).
  • 88% (15/17) of patients that were MRD negative at day 28 remained MRD negative at 6 months.

Broken String Biosciences Appoints Gavin Burns as Vice President of Quality and Operations

Retrieved on: 
Mercredi, novembre 22, 2023
Health, Biometrics, Genetics, Research, Science, Biotechnology, Associate, Quality, DNA, Gene editing, DNA sequencing, Series, Danco Island, Broken, Growth, Doctor of Philosophy, NGS, British Antarctic Survey, University of Gothenburg, Broken String, Genomics

Broken String Biosciences (“Broken String”), a genomics company that has built a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the appointment of Gavin Burns, PhD, as Vice President of Quality and Operations.

Key Points: 
  • Broken String Biosciences (“Broken String”), a genomics company that has built a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the appointment of Gavin Burns, PhD, as Vice President of Quality and Operations.
  • With an extensive background leading quality assurance in the genomics sector, Gavin will be responsible for building and optimizing Broken String’s teams, processes, and systems.
  • Prior to joining Broken String, Gavin held senior quality and operational roles at several UK-based start-ups, most recently serving as Director of Quality and Operations at Biocrucible.
  • To learn more about Broken String Biosciences, please visit brokenstringbio.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20231122788308/en/

The Deerborne Group Announces Poster Presentation at International Society of Liquid Biopsy (ISLB) Annual Conference

Retrieved on: 
Mardi, novembre 14, 2023
DNA sequencing, NGS, International Society, Research, SAN, HIV disease progression rates

SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- The Deerborne Group, a global boutique management consulting firm, today announced they will present new research data at the International Society of Liquid Biopsy (ISLB) annual conference being held in Madrid, Spain November 19-21, 2023.

Key Points: 
  • New research data provides industry with actionable insights into the development and commercialization of novel next generation sequencing (NGS) based liquid biopsy tests.
  • SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- The Deerborne Group, a global boutique management consulting firm, today announced they will present new research data at the International Society of Liquid Biopsy (ISLB) annual conference being held in Madrid, Spain November 19-21, 2023.
  • Next Generation Sequencing (NGS)-based liquid biopsies represent a groundbreaking technology poised to transform the landscape of cancer care.
  • Connect with Jeffrey Jones, Managing Partner at The Deerborne Group, throughout the conference.